Strong Pipeline Not Likely to Influence the Market in the Forecast Period

Wednesday 18 April 2012, Amsterdam

The “Polycythemia Vera Therapeutics - Pipeline Assessment and Market Forecasts to 2019” report is an essential source of information and analysis on the global Polycythemia Vera (PV) therapeutics market. The report identifies the key trends shaping and driving the global PV therapeutics market. It also provides insights into the current competitive landscape and the emerging players expected to significantly alter the market positions of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global PV therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The Polycythemia Vera Therapeutics Market is Forecast to Grow Slowly Until 2019

This analysis estimated the Polycythemia Vera (PV) therapeutics market to be worth $615.71m in 2011. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2.4% over the next eight years, reaching $744.24m by 2019. The growth is attributed to the increasing prevalence of PV leading to an increase in the drug-treated population. The expected launch of Jakafi in Polycythemia Vera (PV) the latter part of the forecast period in the US and the EU (2015) and in Japan (2018), is expected to contribute towards the growth of the PV therapeutics market.

Unmet Need Expected to Remain Unchanged in the Forecast Period

The report estimated the PV therapeutics market has a significant unmet need. Although there are two generic drugs approved for use in the treatment of PV, the market is largely served by generic products that are used off-label. Current treatment options provide only symptomatic relief. Treatment with these drugs also gives rise to adverse effects such as thrombosis and transformation to acute leukemia or myelofibrosis. With safety and efficacy concerns still remaining, a significant opportunity exists for novel products that may effect a cure or exhibit better safety and efficacy profiles than currently used drugs.

Polycythemia Vera Market Competition Expected to Remain Weak

Though there are two generic drugs approved for the treatment of PV, the market is mostly served by drugs that are used off-label. The cytotoxic nature of the approved drugs limits their use in this indication. The disease has been studied for more than ten decades but a proper understanding of its natural history and the mechanism of disease progression is still lacking. This is reflected in the wide use of off-label drugs in the treatment of this disease. This analysis suggests that the current market competition is expected to remain weak during the forecast period, although the expected launch of Jakafi (ruxolitinib) in the latter part of the forecast period may have some impact on the market.

Strong Pipeline Not Likely to Influence the Market in the Forecast Period
This analysis shows that the PV developmental pipeline is strong. Out of a total of seven molecules in the pipeline, there is one first-in-class product, Jakafi (ruxolitinib), in Phase III of development. The remaining six molecules are also first-in-class molecules in the early stages of clinical trials. Though the developmental pipeline is strong, the impact of these molecules may not be seen during the forecast period as all except one are in the early stages of clinical development.